Technology Licensed June 1998

Genomics biotech company providing gene assays to assist pharmaceutical and biotech companies with drug development and expression analysis.

• 15 Employees 
• Expecting $5.0 Million Private Equity Investment 

Cognitive Pharmaceuticals/ Mithridion, Inc.

Cognitive Pharmaceuticals, Ltd. and Mithridion, Inc. have merged forces to develop drugs for Alzheimer’s disease and other serious Central Nervous System disorders. As the surviving entity, Mithridion, Inc. will maintain its headquarters in Madison, WI while the early drug discovery and clinical drug development operations will be located in Toledo, OH. Upon completion of the merger, Mithridion announced the closing of a Series B round in the amount of $2.3 million, which will be used to commence clinical trials of Mithridion’s first drug candidate, MCD-386.

• Mithridion’s IND for MCD-386 cleared on July 2, 2008, and the company commenced a Phase I single dose escalation study in normal volunteers on July 9, 2008.

A company focused on providing thin film solutions to problems associated with the photovoltaic industry such as scratching, soiling and reflection.

• Recently awarded Phase 1 SBIR award for product testing, which is necessary for first sale

A virtual company with technologies in tissue culture and genetic transformation that couple high output, rapid, genotype independent regeneration to high frequency DNA transfer using either Agrobacterium or biolistic transformation.

• Successfully sublicensed technology to Agrivida

The Turning Point, LLC

A manufacturing and marketing firm that produces a state-of-the-art golf exercise and therapeutic device.

• Successful manufacturing partnership established in 2007.
• Now developing phase II prototype Product introduction expected 2nd Q 2008

"A medical device company developing and commercializing a non-invasive glucose measurement technology for use by persons with diabetes.  The consumer ready product is anticipated to operate in similar fashion to a pair of binoculars." 

• The company is working to secure $1.7M of Series A financing
• Preparing for pilot human clinical studies.

Suganit Systems, Inc.

A start-up company involved in the research and development of renewable and clean energy with a focus on ethanol production from biomass

• Still perfecting technology
• Discussions with major multi-national partners progressing

A start-up focused on developing a revolutionary approach for the treatment of threatening clinical conditions. The company’s primary product, pegylated albumin, is a therapeutic colloid-type blood volume expander agent that is superior to human serum albumin.

• Recipient of a $50,000 Ignite Grant from the Regional Growth Partnership 

A start-up company focused on developing a small molecule intervention for obesity, which is one of the most serious public health risks in the United States and worldwide.

• Recipient of a $50,000 Ignite Grant from the Regional Growth Partnership